Partial
Partially Aligned
Patient Risk:
Low
Summary
Most high-level indication/mechanism statements are supported by the provided INSPRA label excerpts, but several dosing/clinical framing and safety-related details are either overstated or not directly supported by the label text provided (e.g., class-level claims about aldosterone blocking and blood-pressure/heart-failure outcome framing; and claims that are specific to “often” use).
Category Scores
Accurate Statements
Eplerenone belongs to the class of mineralocorticoid receptor antagonists.
Section 12.1 Mechanism of Action: binds to mineralocorticoid receptor and blocks aldosterone binding.
Eplerenone blocks aldosterone receptors.
Section 12.1 Mechanism of Action: binds to mineralocorticoid receptor and blocks binding of aldosterone.
Eplerenone is used to treat hypertension.
Section 1.2 Hypertension: indicated for treatment of hypertension in adults to lower blood pressure.
Eplerenone is used to improve survival of stable adult patients with symptomatic HFrEF (≤40%) after an acute myocardial infarction.
Section 1.1 Heart Failure Post-Myocardial Infarction: indicated to improve survival ... symptomatic heart failure with reduced ejection fraction (≤40%) after an acute MI.
Eplerenone is used after myocardial infarction for people at higher risk of developing heart failure or related complications.
Section 1.1 indicates treatment after acute MI in stable adults with symptomatic HFrEF (≤40%), which corresponds to a selected post-MI population.
Unsupported Statements
Eplerenone is used in chronic heart failure to help reduce the risk of worsening heart disease.
The provided label excerpt describes post-MI HFrEF (improve survival) and does not describe chronic heart failure generally as an indication or “reduce risk of worsening heart disease.”
Eplerenone is meant to improve long-term outcomes by blocking aldosterone's effects in the heart and blood vessels.
The provided label excerpt supports survival benefit in post-MI HFrEF (Section 1.1) and mechanism at the mineralocorticoid receptor (Section 12.1), but it does not explicitly state “long-term outcomes,” “heart and blood vessels,” or link those exact phrases.
By blocking aldosterone receptors, eplerenone can reduce fluid retention and lower strain on the heart.
The provided mechanism excerpt states aldosterone binding blockade at the mineralocorticoid receptor but does not explicitly mention fluid retention or lowering strain on the heart.
Reducing fluid retention and lowering strain on the heart helps with both blood pressure control and heart disease management.
The provided excerpts support BP lowering (Section 1.2) and post-MI survival benefit (Section 1.1), but do not explicitly connect “fluid retention/strain” to “both blood pressure control and heart disease management.”
Clinicians most often prescribe eplerenone to reduce risk after a heart attack in selected patients.
The provided label excerpts do not contain statements about prescribing frequency (“most often”).
Clinicians most often prescribe eplerenone to manage chronic heart failure.
The provided label excerpt does not describe chronic heart failure as an indication; also does not state prescribing frequency.
Clinicians most often prescribe eplerenone to treat hypertension in specific situations.
The provided label excerpt supports hypertension treatment in adults to lower blood pressure, but does not state prescribing frequency or use in “specific situations.”
Eplerenone is typically used in situations where a medication that blocks the effects of aldosterone is desired.
The label supports receptor blockade (Section 12.1) but does not phrase the indication as “typically used” for “blocks the effects of aldosterone” desired scenarios.
Contradictions
Important Omissions
No dosing, monitoring, contraindications, or safety details were provided in the AI statements (e.g., initiation/titration doses, potassium monitoring schedule, contraindications for hyperkalemia/renal function/strong CYP3A inhibitors, and hyperkalemia risk management).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The AI statements largely reflect general indications and mechanism, without providing dosing or contraindication-related instructions. However, several statements are not explicitly supported by the provided label (e.g., fluid retention/strain claims and general chronic heart failure use), which could mislead about the precise labeled indications/mechanistic rationale.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not explicitly supported by the provided label excerpts, including general chronic heart failure framing and mechanistic/clinical outcome phrasing (fluid retention/strain, long-term outcomes) and non-label statements about prescribing frequency.
Suggested Improvement
Restrict claims to the exact labeled indications (post-MI stable adult patients with symptomatic HFrEF ≤40% for improved survival; hypertension in adults to lower blood pressure) and the label-supported mechanism (mineralocorticoid receptor binding/blockade of aldosterone). Avoid frequency language (“most often”) and avoid unsupported mechanistic outcome phrasing not present in the provided excerpts.